Introduction {#s1}
============

The APOBEC3 (A3) family of single-stranded cytidine deaminases, are members of the AID/apolipoprotein B mRNA editing enzyme, catalytic peptide-like (APOBEC) deaminases ([@bib19]). These enzymes are involved in important physiological functions such as somatic hypermutation ([@bib47]) and defense against retroelements ([@bib9]; [@bib10]; [@bib53]). However, those with a preference for the cytosine (C) of Tp[C]{.ul}, notably A3A, A3B, A3C, A3F, A3H-1 can contribute to the repertoire of extensive somatic mutations ('mutator phenotype') ([@bib8]) that typify many cancers including the distinctive, strand-coordinated clusters of mutations termed 'kataegis' ([@bib1]; [@bib12]; [@bib13]; [@bib17]; [@bib27]; [@bib44]; [@bib46]; [@bib49]; [@bib56]; [@bib55]; [@bib62]; [@bib63]). In addition to the preference for single-stranded Tp[C]{.ul}, generation of approximately equal amounts of transitions (T) and transversions (A or G) provides a distinctive signature for A3-mediated mutations, which have been found in transiently unpaired regions of DNA that arise during DNA replication, recombination, and transcription ([@bib25]; [@bib28]; [@bib41]; [@bib54]; [@bib60]).

Although A3B is a major source of A3 mutations in some cancers ([@bib12]; [@bib13]) and can be overexpressed as a function of cell proliferation in breast cancers ([@bib15]), the frequency of A3B mutations is not always correlated with A3B expression ([@bib15]; [@bib45]; [@bib56]). Furthermore, the aforementioned single-stranded A3 substrates are also present in non-cancerous cells, and A3 expression is rather ubiquitous ([@bib52]). Therefore, a major issue is why some cancers become sensitized to the activity of APOBEC enzymes and whether it is related to dysregulation of DNA repair.

We had earlier shown that the repair of plasmid-borne mismatches can induce flanking A3-mediated mutations in HeLa cells. Although the mismatches (*e.g.*, U/G) were invariably repaired by base excision repair (BER), this process was sometimes hijacked by non-canonical mismatch repair (MMR), which generates single-stranded APOBEC substrates ([@bib18]). In its simplest form, BER consists of a concerted series of reactions: removal of U by a Uracil-DNA Glycosylase (UDG, UNG in mammals) to generate an abasic (AP) site; scission of the AP site by apurinic/apyrimidinic endonuclease 1 (APE1) to generate a nick with a 3'OH and a 5' deoxyribophosphate (5'dRP); insertion of the complementary base and removal of the 5'dRP by polymerase β (Polβ); ligation of the nick by DNA Ligase I or Ligase III-XRCC1 ([@bib6]; [@bib57]). Because some of these intermediates can be highly mutagenic, these reactions are tightly coupled and sequestered ([@bib24]; [@bib51]). Nonetheless, under certain conditions MMR can access the 3'OH terminated nick, leading to an Exo1-mediated resection that exposes single-stranded DNA opposite to the nicked strand ([@bib29]; [@bib48]; [@bib50]; [@bib58]). Given that thousands of U/G mismatches and AP sites are produced daily ([@bib3]; [@bib4]; [@bib23]), perturbations that compromise the integrity of the BER complex could lead to DNA damage ([@bib24]).

Here we demonstrate in breast cancer cell lines that elevated expression of NEIL2, a bifunctional glycosylase normally involved in oxidative base excision repair ([@bib16]; [@bib21]; [@bib26]; [@bib67]), facilitates A3B-mediated mutations during U/G mismatch repair and induces double-strand breaks (DSBs) in genomic DNA. We further show that purified NEIL2 disrupts canonical BER by outcompeting APE1 for AP sites, thereby providing a possible mechanistic explanation for how this instance of DNA repair dysregulation contributes to the mutational landscape in breast cancer cells.

Results {#s2}
=======

A3B activity is not the only determinant of repair-induced mutations {#s2-1}
--------------------------------------------------------------------

To examine U/G mismatch repair-induced effects in breast cancer cell lines, we transfected shuttle vectors containing no or a U/G mismatch into four established breast cancer cell lines: MCF7, HCC1569, Hs578T and MDA-MB-453, and screened for mutations in the reporter region that flanked the U/G. The reporter region consists of the *E. coli* SupF gene and its promoter on the shuttle vector pSP189-SnA ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Inactivating mutations of the SupF region induced by U/G repair cannot suppress the mutated β galactosidase gene in the MBM7070 *E. coli* strain, resulting in white colonies on the indicator plates ([Figure 1A](#fig1){ref-type="fig"}, bottom row). U/G-repair did not induce mutations in MDA-MB-453, but it did so in Hs578T ([Figure 1B](#fig1){ref-type="fig"}, bottom bar graph), despite similar levels of A3B transcripts ([Figure 1B](#fig1){ref-type="fig"}, upper bar graph) and comparable nuclear T[C]{.ul}-specific deaminase activity ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B,C](#fig1s1){ref-type="fig"}) in these cell lines. The discrepancy between statistically significant amounts of repair-induced mutations and A3B expression also occurred in other cell lines ([Figure 1B](#fig1){ref-type="fig"}). We sequenced the mutated reporter regions of plasmids from all the white colonies, and essentially all of the repair-induced mutations in Hs578T and HCC1569 exhibited an A3 signature, displayed here on the complement of the T[C]{.ul}-containing strand -- thus, G was the most frequently mutated nucleotide and \>70% of mutated bases in Hs578T cells and \>50% in HCC1569 cells involved A[G]{.ul}A, C[G]{.ul}A, or T[G]{.ul}A ([Figure 1D,E](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}).

![A3B activity is not the only determinant of repair-induced mutations.\
(**A**) Schematic depicting the shuttle vector assay to detect U/G MM repair-induced mutations. MM, no mismatch or U/G mismatch. K depicts location of KpnI site. (**B**) Upper panel: qRT-PCR of A3B relative to the housekeeping gene TBP. Lower panel: mutation rate (scored as % of white/total colonies) induced by U/G mismatch repair in MCF7, HCC1569, Hs578T, and MDA-MB-453 breast cancer cell lines. 0 MM, no mismatch; U/G MM, U/G mismatch. Error bars represent s.d., n = 2 for MCF7, HCC1569 and MDA-MB-453 cells; n = 5 for Hs578T cells. ^\*\*^P \< 0.01; ^\*\*\*^P \< 0.001; n.s., no significant difference by two-tailed unpaired Student's *t* test. (**C**) Concentration gradient of in vitro deaminase assay using nuclear extracts from Hs578T and MDA-MB-453 cells against a -T[C]{.ul}T-containing fluorescein-labeled single strand oligonucleotide (39 nt). The amounts of total protein used are listed on top of the gel. The right panel shows quantification of the deamination percentage. The deamination activity is specific for -T[C]{.ul}T- (Figure 1---figure supplement 1B). The time course deamination is shown in Figure 1---figure supplement 1C. S, substrate; P, product. (**D and E**) Mutation matrices and 5'-Trinucleotide context of mutations induced by U/G MM repair in Hs578T (**D**) and HCC1569 (**E**) cells. C is the most frequently mutated base and 70% of the mutated bases are in a 5'-GA (reverse complement of 5'-TC) motif. (**F**) A3B deficiency decreases U/G mismatch repair-induced mutagenesis. 0 MM, no mismatch; U/G MM, U/G mismatch. Error bars represent s.d., n = 3. ^\*\*\*^P \< 0.001 by two-tailed unpaired Student's *t* test.](elife-51605-fig1){#fig1}

Among the seven A3 enzymes, A3A, A3B, A3C, and A3H localize to the nucleus and prefer TC sites ([@bib34]). Quantitative real-time PCR (qRT-PCR) showed that only A3B and A3C were expressed in Hs578T cells ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). Knockdown of A3B by siRNA ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}, left bar graph) reduced both in vitro deaminase activity ([Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}) and the extent of U/G repair-induced mutation rate in Hs578T cells ([Figure 1F](#fig1){ref-type="fig"}), implicating the role of A3B in repair-induced mutagenesis. However, knockdown of A3C ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}, right bar graph) did not affect either in vitro deaminase activity ([Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}) or U/G repair-induced mutation ([Figure 1---figure supplement 2D](#fig1s2){ref-type="fig"}), indicating that A3B was the major deaminase activity involved in the repair-induced mutations in Hs578T cells. That non-mutagenic MDA-MB-453 cells contained a similar level of C-deaminase activity as the mutagenic Hs578T cells ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}) indicates that A3 activity *per se* is not sufficient to cause repair-induced mutations.

NEIL2 facilitates repair-induced mutagenesis {#s2-2}
--------------------------------------------

To explore whether dysregulation of DNA repair sensitized cells to A3B-mediated mutations, we compared the expression of 84 DNA repair enzymes in Hs578T and MDA-MB-453 cells using RT^2^ Profiler PCR array. Consistent with previous RNA-seq data ([@bib33]), most of the tested genes were expressed at lower levels in Hs578T than in MDA-MB-453 ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). However, two genes, NEIL2 and TREX1 were significantly upregulated ([Figure 2A](#fig2){ref-type="fig"}). TREX1 is a 3'−5' exonuclease that degrades cytosolic single and double-stranded DNA, which can illicit an inflammatory innate immune response ([@bib20]). NEIL2 is a bifunctional glycosylase involved in BER of oxidized bases ([@bib16]; [@bib26]; [@bib38]; [@bib67]) and methyl-cytosine demethylation ([@bib59]). NEIL2 catalyzes both base removal and scission of the ensuing AP sites but leaves a 3'-phosphate (3'P) that is removed by PNKP (a polynucleotide 3'kinase and phosphatase) to generate a 3'OH that primes Polβ ([@bib21]; [@bib67]).

![NEIL2 facilitates repair-induced mutagenesis.\
(**A**) Volcano plot of transcription levels of 84 DNA repair enzymes determined by RT^2^ Profiler PCR Array for Hs578T cells (high mutation rate cell line) relative to MDA-MB-453 cells (low mutation rate cell line). Genes significantly downregulated and upregulated in Hs578T cells are highlighted in green and magenta, respectively. Data were generated from four independent determinations ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). (**B**) U/G repair-induced mutation using the shuttle vector assay upon NEIL2 knockdown by siRNA in Hs578T cells. NEIL2 depletion decreased U/G MM repair-induced mutagenesis. siSCR, scramble siRNA; 0 MM, no mismatch; U/G MM, U/G mismatch. Error bar represents s.d., n = 3. ^\*\*\*^P \< 0.001 by two-tailed unpaired Student's *t* test. (**C**) qRT-PCR shows knockdown efficiency of NEIL2 relative to GAPDH in NEIL2-stable-knockdown Hs578T cell lines (shNEIL2\#1 and shNEIL2\#2). shSCR, scramble shRNA; shNEL2\#1 targets NEIL2 3'UTR; shNEIL2\#2 targets NEIL2 ORF. Error bars represent s.d., n = 3. ^\*\*\*^P \< 0.001 by two-tailed unpaired Student's *t* test. (**D**) U/G repair-induced mutation using the shuttle vector assay in NEIL2-stable-knockdown Hs578T cell line. NEIL2 depletion decreased U/G MM repair-induced mutagenesis. 0 MM, no mismatch; U/G MM, U/G mismatch. Error bars represent s.d., n = 3. ^\*^P \< 0.05 by two-tailed unpaired Student's *t* test. (**E**) Rescue of NEIL2 by NEIL2-HA overexpression vector restores U/G mismatch repair-induced mutation rate in NEIL2-stable-knockdown Hs578T cell line shNEIL2\#1 (targets NEIL2 3'UTR). Western blot (left panel) shows NEIL2-HA overexpression for rescue of NEIL2 in shNEIL2-\#1 Hs578T cell line. Lamin B1 serves as a loading control. Error bars represent s.d., n = 3. ^\*^P \< 0.05; ^\*\*^P \< 0.01 by two-tailed unpaired Student's *t* test. (**F**) Overexpression of NEIL2-HA (pPM-NEIL2-3'HA) in MDA-MB-453 cells increased U/G MM repair-induced mutation. Western blot (left panel) shows NEIL2-HA overexpression level in MDA-MB-453 cells. Lamin B1 serves as a loading control. Error bar represents s.d., n = 3. ^\*^P \< 0.05 by two-tailed unpaired Student's *t* test.\
Figure 2---source code 1.Python script for generating the volcano plot in [Figure 2A](#fig2){ref-type="fig"}.qRT-PCR data from RT^2^ Profiler PCR array of Hs578T and MDA-MB-453 is used as the source data ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}).\
Figure 2---source data 1.Original data for DNA repair enzymes screening.RT^2^Profiler PCR screening for 84 human DNA repair genes.](elife-51605-fig2){#fig2}

To determine whether either gene was involved in repair-induced mutations, we depleted NEIL2 or TREX1 by siRNA in Hs578T cells ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}). While NEIL2 knockdown reduced the U/G repair-induced mutation rate by \~70% ([Figure 2B](#fig2){ref-type="fig"}), knockdown of TREX1 had no effect ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). To corroborate the NEIL2 siRNA results, we packaged lentivirus expressing NEIL2 shRNA (\#1 targets NEIL2 3'UTR; \#2 targets NEIL2 ORF) to generate NEIL2-stable-knockdown Hs578T cell lines (shNEIL2\#1 and shNEIL2\#2, [Figure 2C](#fig2){ref-type="fig"}). Consistent with the siRNA knockdown result, repair-induced mutations were reduced in both NEIL2-depleted cell lines ([Figure 2D](#fig2){ref-type="fig"}). Moreover, restoring NEIL2 rescued U/G repair-induced mutations ([Figure 2E](#fig2){ref-type="fig"}). And finally, overexpressing NEIL2 in the low-NEIL2 expression cell line, MDA-MB-453, doubled the U/G repair-induced mutation rate ([Figure 2F](#fig2){ref-type="fig"}). Taken together, these results indicate that NEIL2 facilitates U/G repair-induced mutations.

In addition, we found a positive correlation between U/G repair-induced mutations and the relative NEIL2 expression (qRT-PCR data) in the four breast cancer cell lines ([Figure 2---figure supplement 2A,B](#fig2s2){ref-type="fig"}). These results are consistent with the involvement of NEIL2 in the APOBEC-mediated mutations.

NEIL2 participates in A3B-mediated genomic DNA damage {#s2-3}
-----------------------------------------------------

The above results indicate that the elevated level of NEIL2 in Hs578T cells sensitizes them to the single strand deaminase activity of A3B during DNA repair. Single-stranded DNA is prone to further damage including DSBs, which can be detected as γH2AX foci ([@bib11]; [@bib12]; [@bib35]; [@bib40]; ). Therefore, we used γH2AX foci as a proxy for NEIL2-facilitated, A3B-induced genomic damage. Expression of exogenous A3B generated a statistically significant increase in γH2AX foci, which was markedly decreased in NEIL2-depleted Hs578T cells ([Figure 3A](#fig3){ref-type="fig"}). This was not the result of diminished deaminase activity as A3B deaminase activity generated from the A3B-HA expression vector was unaffected in NEIL2-depleted cell lines ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Rescue of NEIL2 with exogenous NEIL2-HA ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}) restored A3B-induced γH2AX foci in NEIL2-depleted cells ([Figure 3C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). Furthermore, similar to U/G repair-induced mutagenesis ([Figure 2F](#fig2){ref-type="fig"}), expression of NEIL2-HA in non-mutagenic MDA-MB-453 cells increased A3B-mediated γH2AX foci ([Figure 3D](#fig3){ref-type="fig"}). These results indicate that NEIL2 is involved in A3B-induced genomic DNA damage.

![NEIL2 participates in A3B-mediated genomic DNA damage.\
(**A**) Immunostaining of γH2AX foci in NEIL2-stable-knockdown Hs578T cell lines (shNEIL2\#1 and shNEIL2\#2) transfected with A3B-3HA. NEIL2 knockdown decreases the A3B-mediated γH2AX foci. EV, empty vector; shSCR, scramble shRNA. Scale bar, 50 μm. Right panel: Percentage of γH2AX foci, showing mean ± s.d., in at least 10 randomly selected microscopic fields in two replicate experiments for each condition. ^\*\*\*^P \< 0.001 by two-tailed unpaired Student's *t* test. (**B**) In vitro deamination assay of nuclear extracts from NEIL2-stable-knockdown Hs578T cell lines with or without A3B-3HA expression. The substrate was a fluorescein-labeled single-stranded oligonucleotide (39 nt) containing -T[C]{.ul}T- or -A[C]{.ul}T- (negative control). Nuclear extract from HEK293T expressing A3B-3HA (A3B OE) was used as a positive control. NEIL2 knockdown does not affect A3B deaminase activity. Right panel: Quantifications of the cleaved products relative to total DNA loaded onto gel. S, substrate; P, product. (**C**) Quantification of the percentage of cells with γH2AX foci in NEIL2-stable-knockdown Hs578T cell line (shNEIL2\#1) in the absence or presence of a NEIL2 expression vector pcDNA3.1(+)-NEIL2-3'HA. NEIL2 restoration increases A3B-triggered γH2AX foci. Data are represented as mean ± s.d. (n = 10 randomly selected microscopic fields in two replicate experiments). ^\*\*\*^P \< 0.001 by two-tailed unpaired Student's *t* test. The corresponding images of γH2AX foci are shown in [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}. (**D**) Immunostaining of γH2AX foci in MDA-MB-453 cells overexpressing A3B-3HA and NEIL2-HA. Percentage of cells with γH2AX foci is shown in the right panel. EV, empty vector. Scale bar, 50 μm. Data are represented as mean ± s.d. (n = 10 randomly selected microscopic fields in two replicate experiments). ^\*\*^P \< 0.01; n.s., no significant difference by two-tailed unpaired Student's *t* test.](elife-51605-fig3){#fig3}

NEIL2 outcompetes APE1 at AP sites {#s2-4}
----------------------------------

The specificity of NEIL2 for single-stranded oxidized bases predicts that NEIL2 would not directly participate in the repair of the introduced U/G mismatch. However, our results demonstrated that NEIL2 interacts with U/G repair and increases susceptibility to A3B-mediated mutations and DNA damage ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). To gain mechanistic insight into this process we purified human His-tagged NEIL2 protein ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Consistent with previous studies ([@bib26]), NEIL2 exhibited robust glycosylase/lyase activity on hydroxyl-U-containing single-stranded oligonucleotide (ssDNA-OHU), but only trace activity on double-stranded oligonucleotide (dsDNA-OHU/G) ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Furthermore, NEIL2 was inactive on both ssDNA-U and dsDNA-U/G ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). However, the NEIL2 lyase can cleave the AP sites ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}) generated by UDG from U-containing oligonucleotides ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}).

APE1 is the conventional BER AP lyase. Therefore, we determined if NEIL2 collaborates or competes with APE1 for AP sites. APE1 and NEIL2 generate respectively 3'OH and 3'P-terminated fragments ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), which migrate differently on Urea-PAGE ([@bib59]). In a reaction with both NEIL2 and APE1, the NEIL2 product prevailed over the APE1 product (lane 5 of [Figure 4B](#fig4){ref-type="fig"}). Here we used amounts of the proteins just sufficient to completely digest the UDG-generated AP substrates from ss-U oligonucleotides ([Figure 4---figure supplement 3A,B](#fig4s3){ref-type="fig"}, lane 7).

![NEIL2 outcompetes APE1 at AP sites and the NEIL2 product is poor Polβ substrate.\
(**A**) Diagram of AP lyase assay. (**B**) NEIL2 outcompetes APE1 on AP sites generated from 5'-\[^32^P\]-U-containing ssDNA (51 nt) by UDG. Amounts of NEIL2-His~6~ or APE1 are just sufficient to completely cleave the AP site (lane 7 of [Figure 4---figure supplement 3A,B](#fig4s3){ref-type="fig"}). The NEIL2 product retains a 3'P and migrates faster than 3'OH-terminated APE1 product. When both NEIL2 and APE1 are present, only the NEIL2 product is generated (lane 5). S, substrate; P, product. (**C**) Concentration gradient and product accumulation curves of APE1 and NEIL2 on 5'-\[^32^P\]-U-containing dsDNA (35 nt) in the presence of UDG. The volumes of NEIL2 (68 ng/µl) and APE1 (0.005 U/µl) used are listed in the figure. (**D**) NEIL2 competes with APE1 on 5'-\[^32^P\]-U-containing dsDNA (35 nt) in the presence of UDG. The reactions contained either 0.005 U (Low APE1) or 0.02 U APE1 (High APE1) and increasing amounts of NEIL2-His~6~. Lanes 2 and 3 contain respectively 4 μl NEIL2 (68 ng/μl) and 0.02 U APE1. The APE1 cleavage pattern was converted to the NEIL2 pattern with increasing amounts of NEIL2. S, substrate; P, product. (**E**) Incorporation of \[α-^32^P\]-dCTP by Polβ for products generated by APE1, NEIL2, and NEIL2 and PNKP on di-deoxynucleotide (ddC)-modified oligonucleotide in the presence of UDG. P, product. (**F**) Incorporation of \[α-^32^P\]-dCTP by Polβ in the presence of UDG and APE1 as a function of NEIL2 (68 ng/μl, 0, 1, 2, 5, 10 μl) and constant PNKP (127 ng/μl, 2 μl). As the NEIL2 product increasingly dominates the reaction, Polβ incorporation decreases. The number under each band gives the intensity relative to that in the first lane. P, product.](elife-51605-fig4){#fig4}

In contrast to its activity on ssDNA, NEIL2 generated an unexplained double-band product from the dsDNA-U/G oligonucleotides in the concentration gradient assay ([Figure 4C](#fig4){ref-type="fig"}). Double band NEIL2 products have been previously observed ([@bib26]) and in our case were related to the length and composition of the substrate (35 nt, [Figure 4C](#fig4){ref-type="fig"} and 51nt, [Figure 4---figure supplement 3C](#fig4s3){ref-type="fig"}). Though unexplained, these distinct banding patterns provided a convenient way for distinguishing the NEIL2 and APE1 products. To determine whether NEIL2 can compete with APE1 at AP sites generated from dsDNA-U/G oligonucleotides, we gradually increased the concentration of NEIL2 in reactions that contained constant amounts of UDG and APE1. When APE1 was somewhat limiting (0.005U, Low APE1 panel, lanes 4--8, [Figure 4D](#fig4){ref-type="fig"}), the amount of NEIL2 products increased with increasing levels of NEIL2. Notably, the same results were found with excess APE1 (0.02U, High APE1 panel, lanes 9--13, [Figure 4D](#fig4){ref-type="fig"}). These results strongly suggest that NEIL2 supplants APE1 at AP sites. If NEIL2 was merely inhibiting APE1 activity, then the NEIL2 products would likely prevail only at the lower APE1 concentration.

The NEIL2 product is a poor polβ substrate {#s2-5}
------------------------------------------

As the Polβ reaction is a rate-limiting step during BER ([@bib61]), we compared the NEIL2 and APE1 products as substrates for this reaction using His-tagged Polβ purified from *E. coli* ([Figure 4---figure supplement 4A](#fig4s4){ref-type="fig"}). The NEIL2 product retains a 3'P that can be removed by the phosphatase activity of PNKP ([@bib67]). Although Polβ showed robust activity on the APE1 product ([Figure 4---figure supplement 4B](#fig4s4){ref-type="fig"}), it was less active on the NEIL2 product, which depended on PNKP ([Figure 4E](#fig4){ref-type="fig"} and illustration in [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). As expected from the usurpation of AP sites by NEIL2 ([Figure 4B,D](#fig4){ref-type="fig"}), Polβ incorporation was attenuated by NEIL2 ([Figure 4F](#fig4){ref-type="fig"}).

To confirm that our preparation of PNKP contained robust 3'-phosphatase activity, we prepared an oligonucleotide substrate that would yield a 3'-^32^P-terminated product after completion of the coupled glycosylase/scission reactions of bifunctional glycosylases ([@bib67]) ([Figure 4---figure supplement 4C,D](#fig4s4){ref-type="fig"}). As a positive control, the cleavage product generated from this substrate by the *E. coli* bifunctional glycosylase, Fpg, yielded a 3'-^32^P-terminated product that was equally susceptible to the phosphatase activity of either PNKP or T4 polynucleotide kinase ([Figure 4---figure supplement 4E](#fig4s4){ref-type="fig"}). However, in contrast to the complete cleavage of this substrate by Fpg and to NEIL2's complete cleavage of a 5'-terminally labeled substrate ([Figure 4B--D](#fig4){ref-type="fig"} and [Figure 4---figure supplement 3B,C](#fig4s3){ref-type="fig"}), the internally-labeled substrate was resistant to complete cleavage by NEIL2 ([Figure 4---figure supplement 4E](#fig4s4){ref-type="fig"}, lanes 4 and 5). Perhaps these results reflect an isotope effect on NEIL2 activity.

Exo1 generates single-stranded substrates vulnerable to A3B and DNA damage from NEIL2 products {#s2-6}
----------------------------------------------------------------------------------------------

We previously showed that hijacking of BER by mismatch repair (MMR) provided the wherewithal for Exo1 to generate single-stranded DNA for A3B ([@bib18]). However, while NEIL2 has no glycosylase activity toward U/G ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}), it can interrupt normal BER by displacing APE1 at AP sites. As Exo1 can be recruited to endonucleolytic nicks generated by various means ([@bib66]), we determined whether Exo1 was involved in NEIL2-mediated A3B-induced mutations or γH2AX foci. Exo1 siRNA knockdown ([Figure 5A](#fig5){ref-type="fig"}) reduced production of γH2AX foci in Hs578T cells but had no effect in the NEIL2-stable-knockdown cell lines ([Figure 5B,C](#fig5){ref-type="fig"}), indicating that Exo1 activity occurs downstream of NEIL2. In addition, U/G repair-induced mutations were also decreased in Exo1-knockdown Hs578T cells ([Figure 5D](#fig5){ref-type="fig"}). Thus, knockdown of Exo1 recapitulated the effects of NEIL2 knockdown. Furthermore, the nicked AP products generated by APE1 or NEIL2 were equally good substrates for Exo1 despite the different 5' termini of the nicked DNA ([Figure 5E](#fig5){ref-type="fig"}, 5\'dRP for APE1 and 5'P for NEIL2). These results indicate that NEIL2 can divert a BER intermediate to an Exo1-generated single-stranded DNA that is susceptible to A3B deaminase activity, DSBs, or other DNA damage ([Figure 5F](#fig5){ref-type="fig"}).

![Exo1 generates single-stranded substrates vulnerable to A3B and DNA damage from NEIL2 products.\
(**A**) qRT-PCR analysis of siRNA knockdown of Exo1 in NEIL2-stable-knockdown Hs578T cell lines (shNEIL2\#1 and shNEIL2\#2). shNEL2\#1 targets NEIL2 3'UTR; shNEIL2\#2 targets NEIL2 ORF; shSCR, scramble shRNA; siSCR, scramble siRNA. Error bars represent s.d., n = 3. ^\*^P \< 0.05; ^\*\*^P \< 0.01 by two-tailed unpaired Student's *t* test. (**B**) Immunostaining of γH2AX foci in Hs578T cells depleted of Exo1 by siRNA in NEIL2-stable-knockdown Hs578T cell lines. A3B-3HA was expressed in these cell lines for 48 h before immunostaining. Scale bar, 50 μm. (**C**) Quantification of the percentage of cells with γH2AX foci from (**B**). Data are represented as mean ± s.d. (n=10 randomly selected microscopic fields). ^\*\*\*^P \< 0.001; n.s., no significant difference by two-tailed unpaired Student's *t* test. (**D**) Effect of Exo1 depletion on U/G MM repair-induced mutation rate in Hs578T cells. Insert, western blot analysis of Exo1 knockdown efficiency by siExo1 (20 nM siRNA). Lamin B1 serves as a loading control. 0 MM, no mismatch; U/G MM, U/G mismatch. ^\*\*^P \< 0.01 by two-tailed unpaired Student's *t* test. (**E**) APE1 and NEIL2 scission products serve equally well as Exo1 substrates. 5'-phosphorothioate-modified (denoted by asterisk) U-containing oligo (85 nt) was 3'-labeled with cordycepin and used as the substrate for UDG, APE1 or NEIL2, and Exo1(human Exo1 protein). Nuclease products are bracketed. (**F**) Model depicting NEIL2-diversion of BER to Exo1-mediated resection to generate single-stranded A3B substrate.](elife-51605-fig5){#fig5}

Discussion {#s3}
==========

A major unresolved issue in cancer biology is why some cancers become vulnerable to the mutagenic effect of A3 single-stranded deaminases ([@bib2]; [@bib15]; [@bib27]; [@bib49]; [@bib56]), and even more intriguing, that it can be sporadic over clonal lineages of the same tumor ([@bib49]). Although it may be unlikely that a single mechanism would explain every instance of A3-mediated mutations in cancers, we report here that elevated expression of the bifunctional glycosylase, NEIL2 ([Figure 2A](#fig2){ref-type="fig"}), sensitizes Hs578T breast cancer cells to two A3B-mediated effects, repair-induced mutations ([Figure 2B--F](#fig2){ref-type="fig"}) and DNA damage revealed by γH2AX foci ([@bib12]; [@bib35]) ([Figure 3](#fig3){ref-type="fig"}). NEIL2 depletion mitigates both effects, but they are induced by its overexpression. In vitro BER experiments using purified components show that NEIL2, though unable to process U/G mismatches, subverts the BER process that repairs these lesions by usurping the normal BER endonuclease, APE1, at AP sites (the first BER product) ([Figure 4](#fig4){ref-type="fig"}). Although we have not determined why the NEIL2 scission product is a poor substrate for Polβ, the important issue is that it is vulnerable to the 5'−3' exonuclease Exo1 ([Figure 5E](#fig5){ref-type="fig"}), which generates single-stranded DNA susceptible to A3 deaminases. In vivo experiments show that Exo1 and NEIL2 double-knockdown mimics the effect of NEIL2 depletion, indicating that NEIL2 acts upstream of Exo1 ([Figure 5A--C](#fig5){ref-type="fig"}).

Therefore, the most parsimonious explanation of our results is that NEIL2 diverts BER to Exo1-generation of single-stranded DNA that would be vulnerable to A3B deaminase ([Figure 5F](#fig5){ref-type="fig"}). It is also important to stress that the eventual outcome at a given AP site is not likely to be only a function of the relative intracellular concentrations of each protein. APE1 does have other binding partners ([@bib5]; [@bib37]; [@bib64]; [@bib65]) and we presume this is likely also to be true of NEIL2 ([@bib22]). In addition, our results shows that NEIL2, even at a concentration of APE1 that is in four-fold excess of the amount needed to completely digest an AP site, can enzymatically outcompete APE1 ([Figure 4D](#fig4){ref-type="fig"}). The inherent reductive power of a biochemical experiment using purified components is its ability to reveal the prevailing baseline conditions of a process ([Figure 5F](#fig5){ref-type="fig"}).

Several papers reported the presence of single nucleotide polymorphisms (SNPs) in the promoter region of NEIL2 that affected its expression ([@bib7]; [@bib31]; [@bib32]). We sequenced the 700 bp NEIL2 promoter region of the four cell lines that we used, and only the non-mutagenic, low NEIL2-exspressing MDA-MB-453 contained a SNP (rs804271) that had been previously correlated with elevated NEIL2 expression and DNA damage in a BRCA1/2 background ([@bib7]). Thus, additional factors contribute to the regulation of NEIL2 in these cells. We found a positive correlation between U/G repair-induced mutations and relative NEIL2 expression ([Figure 2---figure supplement 2A,B](#fig2s2){ref-type="fig"}), but no relationship to endogenous A3B expression ([Figure 1B](#fig1){ref-type="fig"}), in four breast cancer cell lines. Interestingly, it was recently reported that clonal lineages of MDA-MB-453 can undergo sporadic episodes of A3-mediated mutations ([@bib49]). Thus, it seems that our ATCC isolate of this line (HTB-131) was in a low mutation phase. However, both high and low mutagenic clonal lines from the same lineage of MDA-MB-453 are available ([@bib49]) and would seem to provide the ideal experimental material to investigate by the approaches and methods we report in this paper. Given the heterogeneity of tumor samples, cell lines derived from the breast cancer tissues should also be useful sources of experimental material for investigating the relationship between NEIL2 expression and the mutational processes in tumors.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                    Designation                                          Source or\                              Identifiers                                                                 Additional\
  (species) or\                                                                                         reference                                                                                                           information
  resource                                                                                                                                                                                                                  
  ------------------------------------------------ ---------------------------------------------------- --------------------------------------- --------------------------------------------------------------------------- --------------------------------------------------
  Cell line (*Homo-sapiens*)                       Hs578T, breast cancer                                ATCC                                    HTB-126, RRID:[CVCL_0332](https://scicrunch.org/resolver/CVCL_0332)         Authenticated by ATCC

  Cell line (*Homo-sapiens*)                       MDA-MB-453, breast cancer                            ATCC                                    HTB-131, RRID:[CVCL_0418](https://scicrunch.org/resolver/CVCL_0418)         Authenticated by ATCC

  Cell line (*Homo-sapiens*)                       MCF7, breast cancer                                  ATCC                                    HTB-22, RRID:[CVCL_0031](https://scicrunch.org/resolver/CVCL_0031)          Authenticated by ATCC

  Cell line (*Homo-sapiens*)                       HCC1569, breast cancer                               ATCC                                    CRL-2330, RRID:[CVCL_1255](https://scicrunch.org/resolver/CVCL_1255)        Authenticated by ATCC

  Cell line (*Homo-sapiens*)                       LentiX-293T                                          Clontech                                632180                                                                      Mycoplasma free

  Strain, strain background (*Escherichia coli*)   MBM7070 (*lacZ*^uag_amber^)                          Gift from Dr Michael Seidman (NIH)                                                                                  Electroporation

  Strain, strain background (*Escherichia coli*)   Rosetta (DE3)                                        Millipore                               70954--4                                                                    Protein expression

  Antibody                                         anti-HA (Rabbit polyclonal)                          Sigma-Aldrich                           H6908, RRID:[AB_260070](https://scicrunch.org/resolver/AB_260070)           WB (1:1,000)

  Antibody                                         anti-Exo1 (Rabbit polyclonal)                        Proteintech                             16253--1-AP, RRID:[AB_2278140](https://scicrunch.org/resolver/AB_2278140)   WB (1:1000)

  Antibody                                         anti-Lamin B1(Rabbit polyclonal)                     abcam                                   ab16048, RRID:[AB_10107828](https://scicrunch.org/resolver/AB_10107828)     WB (1:2,000)

  Antibody                                         anti-Rabbit IgG-Peroxidase                           Sigma-Aldrich                           A0545, RRID:[AB_257896](https://scicrunch.org/resolver/AB_257896)           WB (1:10,000)

  Antibody                                         anti-Mouse IgG-Peroxidase                            Sigma-Aldrich                           A4416, RRID:[AB_258167](https://scicrunch.org/resolver/AB_258167)           WB (1:5,000)

  Antibody                                         anti-γH2AX                                           Cell Signaling                          2577, RRID:[AB_2118010](https://scicrunch.org/resolver/AB_2118010)          IF (1:800)

  Antibody                                         Alexa Fluor 568 anti-Rabbit IgG Secondary Antibody   Invitrogen                              A-11036, RRID:[AB_143011](https://scicrunch.org/resolver/AB_143011)         IF (1:500)

  Sequenced-based reagent                          siSCR (negative control)                             Dharmacon                                                                                                           UAGCGACUAAACACAUCAA

  Sequenced-based reagent                          siA3B                                                Dharmacon                               J-017322-08-0005                                                            A3B knockdown

  Sequenced-based reagent                          siA3C                                                Dharmacon\                                                                                                          AAGCCAACGAUCGGAACGAAA
                                                                                                        [@bib42]                                                                                                            

  Sequenced-based reagent                          siNEIL2                                              Dharmacon                                                                                                           GCGAGGAUGAUUCUGAGUA

  Sequenced-based reagent                          siTREX1                                              Dharmacon                                                                                                           ACAAUGGUGACCGCUACGA

  Sequenced-based reagent                          siExo1                                               Dharmacon                                                                                                           CAAGCCUAUUCUCGUAUUU

  Commercial assay or kit                          A3A_TaqMan                                           ThermoFisher Scientific                 Hs02572821_s1                                                               

  Commercial assay or kit                          A3B_TaqMan                                           ThermoFisher Scientific                 Hs00358981_m1                                                               

  Commercial assay or kit                          A3C_TaqMan                                           ThermoFisher Scientific                 Hs00819353_m1                                                               

  Commercial assay or kit                          A3H_TaqMan                                           ThermoFisher Scientific                 Hs00419665_m1                                                               

  Commercial assay or kit                          NEIL2_TaqMan                                         ThermoFisher Scientific                 Hs00979610_g1                                                               

  Commercial assay or kit                          Exo1_TaqMan                                          ThermoFisher Scientific                 Hs01116190_m1                                                               

  Commercial assay or kit                          TREX1_TaqMan                                         ThermoFisher Scientific                 Hs03989617_s1                                                               

  Commercial assay or kit                          GAPDH_TaqMan                                         ThermoFisher Scientific                 Hs02786624_g1                                                               

  Commercial assay or kit                          TBP_TaqMan                                           ThermoFisher Scientific                 Hs00427620_m1                                                               

  Recombinant DNA reagent                          pLKO.1                                               addgene                                 RRID:[Addgene_10878](https://scicrunch.org/resolver/Addgene_10878)          shRNA construction

  Recombinant DNA reagent                          pMDLg/pRRE                                           addgene                                 RRID:[Addgene_12251](https://scicrunch.org/resolver/Addgene_12251)          lentivirus packaging

  Recombinant DNA reagent                          pRSV-Rev                                             addgene                                 RRID:[Addgene_12253](https://scicrunch.org/resolver/Addgene_12253)          lentivirus packaging

  Recombinant DNA reagent                          pMD2.G                                               addgene                                 RRID:[Addgene_12259](https://scicrunch.org/resolver/Addgene_12259)          lentivirus packaging

  Transfected construct (*Homo-sapiens*)           phAPOBEC3B-HA (A3B-3HA)                              NIH AIDS Reagent Program                11090                                                                       A3B overexpression

  Transfected construct (*Homo-sapiens*)           pPM-NEIL2-3'HA                                       abm                                     PV028075                                                                    NEIL2 rescue in mutation rate assay

  Transfected construct (*Homo-sapiens*)           pcDNA3.1(+)-NEIL2-3'HA                               this paper                                                                                                          NEIL2 rescue in γH2AX assay

  Transfected construct (*Homo-sapiens*)           pET22b-NEIL2                                         Gift from Dr Tapas Hazra (U of Texas)                                                                               NEIL2 expression and purification from *E. coli*

  Transfected construct (*Homo-sapiens*)           pET28a(+)-PNKP                                       this paper                                                                                                          For PNKP expression and purification

  Transfected construct (*Homo-sapiens*)           pET28a(+)-Polβ                                       this paper                                                                                                          For Polβ expression and purification
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell culture and transfection {#s4-1}
-----------------------------

Hs578T cells were maintained in DMEM (Gibco, 11965084) with 10% FBS (Gibco, 10082147) and 0.01 mg/ml Insulin (Sigma-Aldrich, I0516) at 37°C in 5% CO~2~. MCF7 cells were maintained in MEM (Gibco, 11095080) with 10% FBS at 37°C in 5% CO~2~. HCC1569 cells were maintained in DMEM with 10% FBS at 37°C in 5% CO~2~. MDA-MB-453 cells were maintained in Leibovitz L-15 media (Gibco, 11415064) supplemented with 10% FBS at 37°C without CO~2~. LentiX-293T and HEK293T cells (a gift from Dr Roland Owens, NIH) were maintained in DMEM with 10% FBS at 37°C in 5% CO~2~. Lipofectamine3000 (Thermofisher Scientific, L3000008) and Mirus TransIT-BrCa transfection reagent (Mirus, MIR 5504) were used for plasmid transfection in breast cancer cells. FuGENE6 (Promega, E2691) was used to transfect plasmids to LentiX-293T and HEK293T cells following the manufacturers' protocol.

Mismatch plasmid construction {#s4-2}
-----------------------------

Mismatch plasmids were constructed as previously described ([@bib18]). For preparation of the gapped vector, we digested 60 μg pSP189-SnA plasmid ([@bib18]) with 120 U nicking endonuclease, Nt.BbvCI (NEB), at 37°C overnight, followed by hybridization with 1,200 pmol biotinylated-complementary oligo at 37°C for 1 hr. The hybridized product was captured by 3 mg Streptavidin Magnetic Particles (Roche, 11641786001) with rotation at 37°C for 2 hr. The gapped vectors were then purified by phenol/chloroform/isoamyl alcohol (25:24:1, PCI) extraction and ethanol precipitation.

For 0 MM and U/G MM reconstitution, 540 pmol C- or U-containing oligonucleotides were annealed at 100-fold molar excess to 18 μg gapped vectors in annealing buffer (100 mM KOAc, 30 mM HEPES, pH 7.5) by incubation at 95°C for 3 min, 40°C for 4 hr, 35°C for 30 s, 30°C for 30 s, and then kept at 25°C. Annealed samples were ligated with T4 DNA ligase (NEB, M0202S) at room temperature (RT, 25°C) for 2 hr, followed by incubation with 0.2 U Klenow Fragment (3'exo^-^,NEB, M0212), 100 μM dNTP, and 1× NEBuffer 2 at 37°C for 10 min to repair any remaining gapped plasmids, which are highly mutagenic ([@bib18]). The mismatch plasmids were purified by PCI extraction and ethanol precipitation. The gapping and ligation efficiencies were monitored by KpnI digestion (one of the two sites is lost after gapping but restored after ligation, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}).

Determination of repair-induced mutations {#s4-3}
-----------------------------------------

Control (0 MM) and mismatch (U/G MM)-containing plasmids (1.5 μg per well in 6-well plate) were transfected into breast cancer cells, extracted 48 hr later using the Wizard Plus SV Miniprep kit (Promega, A1460), and treated with DpnI (NEB, R0176) for 15 min at 37°C. Plasmids (5 ng) were electroporated into 20 μL MBM7070 competent cells. After transformation, the cells were recovered in S.O.C. medium (Invitrogen, 15544--034) for 1 hr at 37°C and plated on LB agar plates containing 100 μg/mL carbenicillin (Sigma-Aldrich, C1389), 1 mM IPTG (Invitrogen, 15529--019), and 0.03% (w/v) Bluo-Gal (Invitrogen, 15519--028). After incubation at 37°C overnight, the plates were stored at 4°C in the dark to allow color development. The percentage of white to total colonies (2,000--3,000) per sample was calculated as 'mutation rate'. For mutation fate and trinucleotide context analysis shown in [Figure 1D,E](#fig1){ref-type="fig"}, we sequenced the reporter region ([Figure 1A](#fig1){ref-type="fig"}) of the pSP189-SnA shuttle vector in all white colonies (ACGT, Inc) using primer R250 (TTTTTGTGATGCTCGTCAGG) ([@bib18]). Mutations were tabulated from the alignments between these sequences and the reference sequence of the starting reporter region.

DNA repair enzymes screening and analysis {#s4-4}
-----------------------------------------

Breast cancer cells were harvested and cDNA was generated as described in the section of 'RNA isolation and qRT-PCR'. The cDNA was quantified by quantitative real-time PCR (qRT-PCR) using RT^2^ Profiler PCR array Human DNA Repair (Qiagen, PAHS-042Z). Raw Ct values were normalized to two housekeeping genes, GAPDH and RPLP0, to determine ΔCt values. MDA-MB-453 ΔCt values were subtracted from Hs578T ΔCt values to obtain ΔΔCt values. Log~2~(fold change) (calculated from log~2~(2^-ΔΔCt^)) was plotted as a function -log~10~(p-value) to generate the volcano plot ([Figure 2A](#fig2){ref-type="fig"}). These values were calculated from ΔCt values (n = 4 replicates) using the ttest_ind function from the Python scipy stats package. Only log~2~(fold change) values above 2 or below −2 and -log~10~(p-value) \> 2 were counted as significant. The python script for generating the volcano plot in [Figure 2A](#fig2){ref-type="fig"} has been uploaded as an additional data file.

RNAi {#s4-5}
----

As preliminary experiments showed no difference in the reduction of NEIL2 transcripts between 10, 20 or 50 nM siRNA transfected with Lipofectamine RNAiMAX (ThermoFisher Scientific, 13778030) using the manufacturer's protocol ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}), we routinely used 10 nM siRNA unless stated otherwise. Cells were harvested 72 hr post-transfection for Western Blot or qRT-PCR analysis. The sequence information for siSCR, siA3B, siA3C, siNEIL2, siTREX1, and siExo1 can be found in the key resources table.

RNA isolation and qRT-PCR {#s4-6}
-------------------------

Total RNA was extracted using the PureLink RNA Mini Kit (Invitrogen, 12183018A), and reverse transcribed using the SuperScript III First-Strand Synthesis System (Invitrogen, 18080--051) following the manufacturer's instruction. The qRT-PCR was performed on StepOnePlus Real-Time PCR System (Applied Biosystems) using TaqMan gene expression assays (listed in the key resources table) and TaqMan Fast Universal PCR Master Mix (Applied Biosystems, 4352042). The 2^-ΔΔCt^ method ([@bib36]) was used to analyze the data.

Lentivirus packaging and generation of stable knockdown cell lines {#s4-7}
------------------------------------------------------------------

We used the 3^rd^ generation packaging system following the addgene pLKO.1-TRC Vector protocol. LentiX-293T cells were transfected with 4 μg pLKO.1 vector containing short hairpin RNA (shRNA) in a 10 cm dish plate along with three packaging plasmids: pMDLg/pRRE (4 μg), pRSV-Rev (2 μg), and pMD2.G (2 μg). Media were replaced with 6 mL fresh complete media 24 hr post-transfection. After another 48 hr, media were harvested and centrifuged at 1,500 ×g for 10 min to remove cells and debris. The viral particles-containing supernatant and 7.5 μg/μl polybrene (Millipore, A-003-E) were added to infect Hs578T cells cultured in 6-well plate (100 μl per well). Media were replaced 24 hr after infection, and fresh media with 2 μg/ml puromycin (Sigma-Aldrich, P8833) were added another 24 hr later to select transfected cells.

shSCR_F:

CCGGGTGGACTCTTGAAAGTACTATCTCGAGATAGTACTTTCAAGAGTCCACTTTTTG

shSCR_R:

AATTCAAAAAGTGGACTCTTGAAAGTACTATCTCGAGATAGTACTTTCAAGAGTCCAC

shNEIL2\#1_F:

CCGGTCAGAGGTGCCAGTAGTATAACTCGAGTTATACTACTGGCACCTCTGATTTTTG

shNEIL2\#1_R:

AATTCAAAAATCAGAGGTGCCAGTAGTATAACTCGAGTTATACTACTGGCACCTCTGA

shNEIL2\#2_F:

CCGGGGGCAGCAGTAAGAAGCTACACTCGAGTGTAGCTTCTTACTGCTGCCCTTTTTG

shNEIL2\#2 \_R:

AATTCAAAAAGGGCAGCAGTAAGAAGCTACACTCGAGTGTAGCTTCTTACTGCTGCCC

shNEL2\#1 targets NEIL2 3'UTR, and shNEIL2\#2 targets NEIL2 ORF. All oligonucleotides used in this paper were synthesized by Integrated DNA Technologies (IDT) unless otherwise stated.

Expression plasmids {#s4-8}
-------------------

Human NEIL2, PNKP and Polβ cDNAs were amplified from Hs578T cDNA using Q5 High-Fidelity DNA Polymerase (NEB, M0491) with the indicated forward and reverse primers and cloned into the indicated vectors:

NEIL2

F-NEIL2-EcoRI: TTT[GAATTC]{.ul}ATGCCAGAAGGGCCGTTGGTG

R-NEIL2-XhoI: AAA[CTCGAG]{.ul}GGAGAACTGGCACTGCTCTGG

pcDNA3.1(+)−3'HA vector (with a HA tag inserted at the C-terminus, a gift from Dr. Zhengfan Jiang at Peking University).

PNKP

F-PNKP-EcoRI: AAA[GAATTC]{.ul}ATGGGCGAGGTGGAGGCCC

R-PNKP-HindIII: AAA[AAGCTT]{.ul}TCAGCCCTCGGAGAACTGGC

Polβ

F-Polβ-BamHI: TTT[GGATCC]{.ul}ATGAGCAAACGGAAGGCGCCG

R-Polβ-HindIII: AAA[AAGCTT]{.ul}TCATTCGCTCCGGTCCTTGGGTT

Both cDNAs were cloned onto pET28a(+) vector (His-tagged, kindly provided by Dr. Wei Yang at NIH).

The underlined nucleotides denote restriction sites.

Western blotting {#s4-9}
----------------

Cells were harvested and centrifuged at 2,000 *×g* for 2 min. For nuclear proteins, cells were lysed in RIPA buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 1% Sodium deoxycholate, 0.1% SDS) supplemented with protease inhibitor cocktail (Roche, 04693159001), and centrifuged at 13,000 *×g* for 10 min at 4°C. For western blotting, the proteins were separated on NuPAGE gels (Novex) and transferred to PVDF membranes (Novex, LC2002). After blocking with 3% BSA (in TBST: 50 mM Tris-Cl, pH 7.5, 150 mM NaCl, and 0.06% Tween-20), membranes were probed with primary antibodies at 4°C overnight. The membranes were washed three times in TBST (with 0.06% Tween-20), incubated with anti-Rabbit or anti-Mouse IgG-Peroxidase at RT for 1.5 hr, then treated for 5 min with SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher Scientific, 34580) and exposed to X-ray film.

Immunofluorescence {#s4-10}
------------------

Hs578T cells seeded in 6-well plates were transfected with 1.5 μg phAPOBEC3B-HA (A3B-3HA) plasmid, and 24 hr post-transfection, the cells were seeded into Lab-Tek II Chamber Slide System (Nunc, 177380). After another 24 hr, the cells were washed with pre-warmed PBS, and fixed in 4% Formaldehyde (ThermoFisher Scientific, 28906, diluted with PBS) at 37°C for 15 min. Cells were washed three times with PBS and then permeabilized in 0.1% Triton X-100 (Sigma-Aldrich, T8787) at RT for 10 min, followed by another wash with PBS. For immunostaining, cells were blocked with 1% BSA (in PBS) at RT for 30 min, and incubated with anti-γH2AX primary antibody overnight at 4°C. After washing with PBS three times, cells were blocked with 1% BSA (in PBS) at RT for 30 min and then incubated with Alexa Fluor 568 anti-Rabbit IgG secondary antibody at RT for 2 hr. Cells were washed with PBS three times, mounted with Prolong Diamond Antifade Mountant with DAPI (Life technologies, P36962) and cured overnight at RT. Slides were imaged using a Keyence Digital Microscope and images were analyzed with Fiji (ImageJ) software using identical acquisition parameters for all images.

Effect of expressing NEIL2-HA in NEIL2-stable-knockdown Hs578T cells {#s4-11}
--------------------------------------------------------------------

NEIL2-stable-knockdown (shNEIL2\#1) and the negative control scramble shRNA-stable Hs578T cell lines were transfected with 1 μg pcDNA3.1(+)-NEIL2-3'HA or empty vector on the same day of cell seeding in 6-well plates. After 16 hr, the cells were transfected with 1.5 μg phAPOBEC3B-HA. The cells were re-seeded into a Nunc Lab-Tek II Chamber Slide System and underwent the γH2AX immunofluorescence procedure 24 hr later as described above.

Purification of recombinant proteins {#s4-12}
------------------------------------

This purification protocol was kindly provided by Dr. Tapas Hazra at University of Texas. Plasmid pET22b-NEIL2, pET28a(+)-PNKP, or pET28a(+)-Polβ was transformed into Rosetta DE3 competent cells and protein expression in 500 mL cultures was induced with 0.5 mM IPTG at 16°C overnight. Cell pellets were collected by centrifugation, washed with PBS, and resuspended in 20 mL lysis buffer (25 mM Tris, pH 7.5, 500 mM NaCl, 1 mM EDTA, 10% glycerol, 10 mM β-mercaptoethanol, 5 mM imidazole, 0.25% Tween-20, and 1 mM PMSF). Suspensions were sonicated on ice (40% Amp, 30 s ON and 30 s OFF) for 5 min, followed by addition of Triton X-100 to a final concentration of 0.25%. The lysate was centrifuged at 4,000 rpm at 4°C for 30 min. The supernatant was applied to pre-equilibrated Ni-NTH agarose resin (Qiagen, 30230) and rotated for 2 hr in cold room. The resin was washed three times with increasing concentrations of imidazole (10 mM, 20 mM, and 40 mM) in wash buffer (25 mM Tris, pH7.5, 500 mM NaCl, 1 mM EDTA, 10% glycerol, 10 mM β-mercaptoethanol, and 0.25% TritonX-100). Elution buffer (25 mM Tris, pH 7.5, 300 mM NaCl, 0.5 mM EDTA, 10% glycerol, 10 mM β-mercaptoethanol, 0.25% TritonX-100, and 400 mM imidazole, 800 μl) was added to the resin and rocked at 4°C for 30 min. The resin was centrifuged at 600 rpm for 3 min at 4°C and the supernatant was retained. Another 800 μl of elution buffer were added to the matrix for a second elution, and the eluents were combined and dialyzed against 1 L of storage buffer (25 mM Tris, pH 7.5, 300 mM NaCl, 0.1 mM EDTA, 50% glycerol, 0.25% TritonX-100, and 2 mM TCEP) in a D-Tube Dialyzer (Millipore, 71510--3) with constant stirring at 4°C. Purified proteins were quantified using Pierce BCA Protein Assay Kit - Reducing Agent Compatible kit (ThermoFisher Scientific, 23250), aliquoted, and stored at −20°C.

DNA deaminase activity {#s4-13}
----------------------

Deamination assays were performed as previously described ([@bib14]; [@bib39]). For nuclei isolation, breast cancer cells were harvested, washed with 1× PBS. The cells were resuspended in hypotonic buffer (20 mM Tris, pH7.5, 0.1 mM EDTA, 2 mM MgCl~2~) and incubated at RT for 2 min and then on ice for 10 min, followed by adding 1/10 vol of 10% NP-40 (ThermoFisher Scientific, 28324) and centrifugation at 1,000 *×g* for 5 min at 4°C to pellet the nuclei. Extracts of HEK293T cells expressing A3B-3HA or isolated breast cancer nuclei were prepared by lysis in M-PER mammalian protein extraction reagent (ThermoFisher Scientific, 78501), supplemented with protease inhibitor cocktail (Roche, 04693159001) and 100 mM NaCl (final concentration). After lysis, glycerol (final concentration, 10%, vol/vol) was added and the resulting mixture was centrifuged at 13,000 *×g* for 10 min at 4°C. Total protein concentration was quantified by Pierce BCA Protein Assay Kit (ThermoFisher Scientific, 23225).

Whole cell or nuclear extracts were incubated with RNase A (ThermoFisher Scientific, EN 0531) at 37°C for 15 min before adding 500 nM fluorescein-labeled oligonucleotides (39 nt, synthesized by the Midland Certified Reagent Company, Inc) and 2U UDG (NEB, M0280) in 10 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM DTT, 1 mM EDTA. Reactions were incubated at 37°C for up to 5 hr followed by treatment with 150 mM NaOH at 37°C for 20 min. After heating at 95°C for 3 min, samples were immediately chilled on ice and purified by PCI extraction and ethanol precipitation. Samples were heated for 3 min at 95°C with an equal volume of 2× Novex TBE-Urea Sample Buffer (Invitrogen, LC6876), separated by 12% 8M Urea PAGE gels, and imaged using the Fujifilm FLA-5100 (Fujifilm Life Science).

39 nt -TCT-:5\'-fluorescein-AATAATAATAATAATAAT[TCT]{.ul}AATAATAATAATAATAAT-3\'

39 nt -ACT-:5\'-fluorescein-AATAATAATAATAATAAT[ACT]{.ul}AATAATAATAATAATAAT-3\'

^32^P labeling and oligonucleotides annealing {#s4-14}
---------------------------------------------

For 5'-end ^32^P labeling, 30 pmol of oligonucleotide were incubated with 1× T4 PNK Buffer (NEB, B0201S), 20 U T4 Polynucleotide Kinase (NEB, M0201S), and 35 pmol \[γ-^32^P\]-ATP (PerkinElmer, 3000 Ci/mmol) for 30 min at 37°C followed by 65°C for 20 min. For 3'-end ^32^P labeling, 20 pmol oligonucleotides were incubated with 1× TdT buffer (NEB, B0315S), 0.25 mM CoCl~2~ (NEB, B0252S), 40 U terminal transferase (NEB, M0315S), and 40 pmol cordycepin (PerkinElmer, 800 Ci/mmol) for 30 min at 37°C followed by 70°C for 10 min. Unincorporated nucleotides were removed using Illustra ProbeQuant G-50 Micro Columns (GE Healthcare, 28903408) following the manufacturer's instructions. ^32^P-labeled oligonucleotides were annealed to 2-fold molar excess of unlabeled complementary oligonucleotides in IDT annealing buffer (30 mM HEPES, pH 7.5, and 100 mM KOAc) by heating at 94°C for 2 min followed by a slow cooling to RT.

NEIL2 and APE1 glycosylase/lyase activity assay {#s4-15}
-----------------------------------------------

NEIL2 activity was measured as previously described ([@bib38]). Briefly, 0.5 pmol ^32^P-labeled oligonucleotide substrate (35 nt or 51 nt) was mixed on ice with 1 μl UDG (1 U/μl) (NEB, M0280S), and purified NEIL2 (68 ng/µl) or APE1 (NEB, M0282S, 0.005 U/µl), and 1× NEBuffer 4 (50 mM KOAc, 20 mM Tris-Acetate, pH 7.9, 10 mM Mg(OAc)~2~, 1 mM DTT) in a total reaction volume of 10 μl. Reactions were incubated at 37°C for 30 min. After PCI extraction and ethanol precipitation, samples were treated with equal volume of 2× Novex TBE-Urea Sample Buffer (Invitrogen). Cleaved products were separated using 12% 8 M Urea PAGE, then exposed to X-ray film.

For competition assays between NEIL2 and APE1, cleaved products were separated using 20% 8M Urea PAGE. For double-stranded DNA (dsDNA), 1 pmol ^32^P-labeled dsDNA (35 nt) was mixed on ice with UDG (1 U/μl, 1 μl), various concentrations of purified NEIL2 or APE1 (indicated in figures and legends), and 1× NEBuffer 4 in 20 μl reactions. After incubation at 37°C for 30 min, the reaction products were extracted by PCI followed by ethanol precipitation. The samples were treated with an equal volume of 2× Novex TBE-Urea Sample Buffer (Invitrogen), heated at 95°C for 3 min, and chilled on ice before subjecting to 20% 8 M Urea PAGE.

51-nt single strand U:

5'-GCTTAGCTTGGAATCGTATCATGTA(U)ACTCGTGTGCCGTGTAGACCGTGCC-3'

51-nt single strand hydroxyl-U:

5'-GCTTAGCTTGGAATCGTATCATGTA(OHU)ACTCGTGTGCCGTGTAGACCGTGCC-3'

51-nt bottom strand:

5'-GGCACGGTCTACACGGCACACGAGTGTACATGATACGATTCCAAGCTAAGC-3'

35-nt single strand U: 5'-GCCCTGCAGGTCGA(U)TCTAGAGGATCCCCGGGTAC-3'

35-nt bottom strand: 5'-GTACCCGGGGATCCTCTAGAGTCGACCTGCAGGG-3'

Polβ incorporation assay {#s4-16}
------------------------

The substrate was the previously reported ([@bib6]) 35 nt double-stranded oligonucleotide containing a U/G pair modified by addition of 3'-dideoxycytidine (3ddC) to block end incorporation. Incorporation reactions (20 μl) were assembled on ice and contained 1× NEBuffer 4 (50 mM KOAc, 20 mM Tris-Acetate, pH 7.9, 10 mM Mg(OAc)~2~, 1 mM DTT), 25 nM 35 bp dsDNA, 1.25 U/μl UDG, 0.6 × 10^6^ dpm/pmol \[α-^32^P\]-dCTP (1:10 diluted in 5 nM dCTP, 2 μl) and the indicated amounts of APE1 (0.01 U/μl, 1 μl), purified NEIL2 (68 ng/μl, 2.5 μl), PNKP (127 ng/μl, 2 μl) and Polβ (1.7 ng/μl, 2 μl). In the competitive incorporation assay ([Figure 4F](#fig4){ref-type="fig"}), the PNKP for each reaction was held constant and the amount of NEIL2 was increased as indicated in the figure legend. The reactions were initiated by adding the proteins, incubated at 37°C for 15 min, and then terminated with 100 mM EDTA, followed by PCI extraction and ethanol precipitation. The products were treated with an equal volume of 2× Novex TBE-Urea Sample Buffer (Invitrogen), separated using 12% Urea PAGE, and exposed to X-ray film.

Top_U\_3ddC_35: GCCCTGCAGGTCGA(U)TCTAGAGGATCCCCGGGTA/ddC/

Bottom_G\_3ddC_35: GTACCCGGGGATCCTCTAGAGTCGACCTGCAGGG/ddC/

3' phosphatase activity of PNKP {#s4-17}
-------------------------------

A 26 nt oligonucleotide with U at the 5' end was labeled with ^32^P by T4 PNK (NEB) as described above. As illustrated in [Figure 4---figure supplement 4C](#fig4s4){ref-type="fig"}, the oligonucleotide was annealed to a 51 nt complementary oligonucleotide, and then annealed to a 25 nt oligonucleotide in annealing buffer (10 mM Tris, pH 7.5, 50 mM NaCl, 1 mM EDTA), followed by ligation with T4 DNA ligase (NEB) to form an internally-labeled duplex oligonucleotide (designated S, [Figure 4---figure supplement 4C](#fig4s4){ref-type="fig"}). The oligonucleotide (2 pmol) was treated with UDG (1 U, NEB) and Fpg (1U, NEB) or NEIL2 (272 ng) in a 10 μl reaction at 37°C for 30 min. The products were purified by PCI extraction and ethanol precipitation and treated with PNKP (25 mM HEPES-KOH, pH 7.6, 50 mM NaCl, 0.5 mM EDTA, 0.5 mM DTT, 100 ng/ml BSA, 5% Glycerol) or T4 PNK (70 mM Tris-HCl, 10 mM MgCl~2~, 5 mM DTT, pH 6.0) at 37°C for 30 min. The reactions were stopped on ice for 10 min and then analyzed by 20% Urea PAGE as described above.

Top_25_left: GCTTAGCTTGGAATCGTATCATGTA

Top_26_U\_right: UACTCGTGTGCCGTGTAGACCGTGCC

Bottom_51:GGCACGGTCTACACGGCACACGAGTGTACATGATACGATTCCAAGCTAAGC

Exo1 nuclease assay {#s4-18}
-------------------

The dsDNA substrates for the resection assay were 85 nt oligonucleotides, which contained a 5'-phosphorothioate modification to block end resection by exonuclease. The 85 nt U-containing (U at position 43) oligonucleotides were 3'-labeled with ^32^P-cordycepin and then annealed with the bottom strand before treatment with UDG and APE1 or NEIL2 as described above. After PCI purification and ethanol precipitation, 0.1 pmol dsDNA substrates were incubated with Exo1 (human Exo1 protein, kindly provided by Dr. Tanya Paull at the University of Texas at Austin) ([@bib43]) resection assay in a 10 μl reaction as previously described ([@bib30]). The reactions were carried out at 30°C for 15 min and then purified by PCI extraction and ethanol precipitation. The products were mixed with an equal volume of 2× Novex TBE-Urea Sample Buffer (Invitrogen) and heated at 90°C for 3 min. Samples were subjected to 20% Urea PAGE and exposed to X-ray film.

Top_U\_5'phosphorothioate_85: 5'G\*A\*C\*AGGATCCGGGCTAGCATCTTCATACGCCCTGCAGGTCGAUTCTAGAGGATCCCCGGGTACCTTCATACATAGTTGTCACTGG3'

Bottom_G\_5'phosphorothioate_85: 5'C\*C\*A\*GTGACAACTATGTATGAAGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGGGCGTATGAAGATGCTAGCCCGGATCCTGTC3'

\* denotes phosphorothioate

Quantification and statistical analysis {#s4-19}
---------------------------------------

Statistical details, including the statistical methods, n values, definition of significance, and definition of mean value and dispersion were indicated in the figure legends. Statistical analyses were carried out using GraphPad Prism 8.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

In this manuscript, the authors investigated the mechanism underlying the variable frequency of mutagenesis induced by the APOBEC3B (A3B) deaminase in breast cancer. A known pathway for repair of U/G mismatches involves the removal of the uracil, creating an apurinic/apyrimidinic (AP) site that is further processed by the activity of AP endonuclease 1 (APE1) to generate nicks with a 3\' OH group. Such nicks are recognized and repaired by DNA polymerase β activity followed by Ligase 1 or III/XRCC1 mediated ligation. The authors have discovered that in some cells, NEIL2 displaces APE1 to create a product with a 3\' phosphate group that is unsuitable for processing by DNA polymerase β. This product triggers an alternative cascade of reactions involving exonuclease 1, forming single stranded DNA that is susceptible to A3B activity, thus enhancing mutagenesis and inducing double stranded DNA breakage. The enhancement of A3B activity by this interaction can help provide a mechanistic basis for the observation that in many cancers, A3B expression levels are not good predictors of A3B-induced mutagenesis.

**Decision letter after peer review:**

Thank you for submitting your article \"Perturbation of base excision repair sensitizes breast cancer cells to APOBEC3 deaminase-mediated mutations\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Jeffrey Settleman as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The APOBEC3 deaminase-mediated mutation phenotype in breast cancer has been highlighted in many studies. In this manuscript, the authors investigated the mechanism underlying the variable frequency of mutagenesis induced by APOBEC3B (A3B) in breast cancer. A known pathway for repair of U/G mismatches involves the removal of the uracil, creating an apurinic/apyrimidinic (AP) site that is further processed by the activity of AP endonuclease 1 (APE1) to generate nicks with a 3\'OH group. Such nicks are recognized and repaired via the activity DNA polymerase β followed by Ligase 1 or III/XRCC1 mediated ligation. The current study reports that in some cells, NEIL2 displaces APE1 to create a product with a 3\' phosphate group that is unsuitable for processing by DNA polymerase β. This product triggers an alternative cascade of reactions involving exonuclease 1, forming single stranded DNA that is susceptible to A3B activity, thus enhancing mutagenesis and inducing double stranded DNA breakage. The enhancement of A3B activity by this interaction can help provide a mechanistic basis to the observation that in many cancers, A3B expression levels are not good predictors of A3B-induced mutagenesis.

The manuscript is written clearly and provides data that are generally supportive of the hypothesis, but several concerns need to be addressed. In addition, as currently written, certain methodological points are explained very succinctly, making the interpretation difficult. The manuscript will be improved by a clearer Introduction to the methodology and by including additional data, some of which includes cell-based assays, and statistical tests to address the concerns listed below.

Essential revisions:

1\) The deaminase activity assay presented in Figure 1B comparing two different cell\'s nuclear extracts is showing fast saturation (not linear), authors might consider doing a time-kinetics to give a better representation and also add recombinant A3B protein as a control. Together with A3B mRNA expression, to connect with A3B function, authors should consider checking protein level in different breast cancer cell lines.

2\) In all the deaminase activity assays HEK293T A3B O/E nuclear extract is showing much higher activity. Thus, authors should show NEIL2 and APE1 protein levels in those extracts to identify rate-limiting inhibitory components present in breast cancer cell lines and to support the model.

3\) Figure 2F and 2G are either missing error bars or appear to be not statistically significant. Western blots need to be provided with all the deaminase assay of knockdown experiments and rescue experiments. If NEIL2 is substituting APE1 activity, then APE1KD should display higher mutator phenotype in these cells or overexpression of APE1 should decrease the mutation rate in NEIL2 overexpressing HS578T cells. Cell-based experiments are needed to support the competition between APE1 and NEIL2.

4\) In Figure 3A, it seems that γH2AX staining increased in all cells upon the expression of A3B and that shNEIL2 diminished this effect but did not completely prevented it as written in the Results section. It would be good to modify the text to reflect this result. Figure 3D shows the results of a γH2AX assay in the non-mutagenic MDA-MB-453 that were subject to exogeneous expression of both A3B and NEIL2. The control shows a γH2AX assay in A3B expressing cells but the background of γH2AX expression in the parental cells is not shown. Because the experiments aim to measure A3B-mediated γH2AX foci, quantification of such foci in the parental cells is essential for interpreting the results. Additionally, the results from the γH2AX experiments in Figure 3A need to be further supported by immunoblotting for γH2AX and total H2AX. The same concern applies to the experiments in Figure 5B.

5\) APE1 is known to be a poor enzyme for a single-stranded substrate as it needs a double strand to bind and cleave efficiently. Thus, that can explain APE1\'s reduced activity in Figure 4A. For double-stranded substrate APE1 activity seems much faster. Again, the kinetics seems little off as the substrate to product ratio is not consistent. It looks like double-stranded oligo is not a suitable substrate for NEIL2. APE1 is much faster, and a higher concentration of NEIL2 can compete for only 50% activity. Figure 4C and D is very complex to understand; in Figure 4C, it seems NEIL2 is bound to UDG substrate that inhibits APE1 activity. Thus, NEIL2 has slower turnover from the substrate. But Figure 4D demonstrates a higher amount of APE1 facilitates NEIL2 activity. In this regard, measuring dissociation constant from the substrate can be useful to dissect the issue of activity vs. enzyme turnover. Figure 4F aims to test whether processing by NEIL2 creates products that are poor substrates for DNA polymerase β. This is a key point in the paper and quantification is important. In the experiment reported in the current submission, NEIL2 levels vary along with PNKP levels, and interpretation is therefore difficult. It would be useful to perform the NEIL2 dose-response analysis in the presence of a constant level of PNKP.

6\) A substrate using THF as an AP site substitute can be used as a control. Also using a substrate with 3\'P rather than UDG can be a cleaner set-up to compare.

7\) Although the authors stated that Exo1 activity is similar for both APE1 and NEIL2 products, Figure 5E shows different substrate to product ratios for two enzymes. Authors might consider adding a panel of APE1 and NEIL2 together in Exo1 activity assay in Figure 5E to understand if the presence of APE1 facilitates or inhibits Exo1 activity.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Perturbation of base excision repair sensitizes breast cancer cells to APOBEC3 deaminase-mediated mutations\" for further consideration by *eLife*. Your revised article has been evaluated by Jeffrey Settleman (Senior Editor) and a Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

The authors have addressed an important concern, providing better descriptions of the specialized methodology used in the paper. The authors have also removed some controversial data from the paper, resulting in a succinct, readable and focused report. However, some controls are still missing:

1).An experimental validation of the proposed competition between APE1 and NEIL2 (usurpation of APEI by NEIL2) is critical. A ChIP-seq or a chromatin binding assay can be used for this purpose. If validated, this point is potentially very important, as is emphasized in the Abstract.

2\) Due to the absence of appropriate measurements of protein levels (for example, NEIL2 and APE1 in nuclear extracts that show variable activity in deaminase assays) it is not possible to rule out that the observations reported in the paper might be explained by alternative mechanisms. If appropriate antibodies are not available, these other mechanisms should at least be discussed.

3\) The authors are correct to suggest that immunofluorescence is an acceptable measure of DNA damage in some literature. However, because of the high signal-to-noise ratio in the current submission, the paper would still benefit from another measurement of the extent of DNA damage based on a different method, for example, immunoblotting of γH2AX vs. total H2AX.

For the quantification of immunofluorescent signals in Figure 3 (A, right panel, C and D): what does the y-axis (% of γH2AX positive cells) refer to? Does each data point refer to a replicate experiment, or was the percentage of positive cells determined in each field in a single imaging experiment? How significant are the changes induced by the two shNEIL2 when compared to control levels?

10.7554/eLife.51605.sa2

Author response

> Essential revisions:
>
> 1\) The deaminase activity assay presented in Figure 1B comparing two different cell\'s nuclear extracts is showing fast saturation (not linear), authors might consider doing a time-kinetics to give a better representation and also add recombinant A3B protein as a control. Together with A3B mRNA expression, to connect with A3B function, authors should consider checking protein level in different breast cancer cell lines.

We addressed the reviewer's suggestions as follows: For Figure 1B in the original submission, we prepared new nuclear extracts from the two breast cancer cells, assayed them over a range of concentrations (0, 5, 15, 25, and 35 μg), and quantified the deamination percentage (Figure 1C in the revised manuscript). As recommended, we added A3B-expressing HEK293T cell extract as a control (Figure 1C in the revised manuscript). In addition, we performed a time course for the in vitro deamination assay using 25 μg of nuclear extract from the breast cancer cells over the following hourly time intervals: 0, 0.5, 1, 2, 4, and 5, using an A3B-expressing HEK293T cell extract as a control (Figure 1---figure supplement 1C in the revised manuscript).

We agree with the reviewer that relating the amount of deaminase protein is a more valid reflection of A3B activity than A3B mRNA. In an attempt to do so, we tested two commercial anti-A3B antibodies (abcam, ab184990; Proteintech, 14559-1-AP). While neither were sufficiently sensitive to recognize endogenous A3B, they did recognize exogenous A3B from an expression vector ([Author response image 1A,B](#respfig1){ref-type="fig"}). This probably explains why a number of A3B studies only report mRNA levels (e.g. Burns et al., 2013; Cescon et al., 2015; Law et al. Sci. Adv. 2016). Thus, we used the in vitro deaminase assay to measure A3B activity in the breast cancer cell lines (Figure 1C and Figure 3B in the revised manuscript).

![Commercially available anti-A3B antibodies do not recognize endogenous A3B protein.\
(**A**) 100 μg whole cell lysate from MDA-MB-453 and Hs578T cells were subject to western blotting and detected by anti-A3B antibodies shown. Lamin B1 serves as a loading control. (**B**) 100 μg whole cell lysate from Hs578T cells overexpressing empty vector or A3B-3HA were subject to western blotting and detected by anti-A3B antibodies shown. Both antibodies recognize overexpressed A3B-3HA but not endogenous A3B. HEK293T overexpressing A3B-3HA lysate detected by anti-HA antibody was used as a positive control. LaminB1 serves as a loading control.](elife-51605-resp-fig1){#respfig1}

> 2\) In all the deaminase activity assays HEK293T A3B O/E nuclear extract is showing much higher activity. Thus, authors should show NEIL2 and APE1 protein levels in those extracts to identify rate-limiting inhibitory components present in breast cancer cell lines and to support the model.

An essential element of our model is that the extent of U/G repair-induced mutations is not solely dependent on the level of A3B deaminase, but also, or even more so, on the availability of the A3B single-stranded substrate. We surmised this when we compared and found that the extent of U/G-repair induced mutations was not correlated with either the amount or the activity of A3B deaminase in nuclear extracts of breast cancer cells (Figure 1B,C in the revised manuscript). To measure the A3B deaminase activity for each cell line, we extracted their nuclear extracts and used the in vitro deamination assay as depicted in [Author response image 2](#respfig2){ref-type="fig"}: equivalent amounts of A3B-preferred-TCT-containing single-stranded oligonucleotide was used as the substrate. As the deamination activity is only dependent on the amount of A3B in the nuclear extract, the cell extract of HEK293T cells overexpressing A3B (used as a positive control) would be expected to contain considerably higher activity than the nuclear extract of breast cancer cells (endogenous level, Figure 1C and Figure 1---figure supplement 1B,C in the revised manuscript).

![Schematic of the in vitro deamination assay.](elife-51605-resp-fig2){#respfig2}

The deamination assays did not speak to the relative amounts of NEIL2 or APE1 in these extracts. After we obtained results in Figure 1B,C shown in the revised manuscript, we screened the breast cancer cell lines for their expression of DNA repair enzymes (Figure 2A in the revised manuscript) and found that repair-induced mutagenesis was correlated with elevated levels of NEIL2.

> 3\) Figure 2F and 2G are either missing error bars or appear to be not statistically significant. Western blots need to be provided with all the deaminase assay of knockdown experiments and rescue experiments. If NEIL2 is substituting APE1 activity, then APE1KD should display higher mutator phenotype in these cells or overexpression of APE1 should decrease the mutation rate in NEIL2 overexpressing HS578T cells. Cell-based experiments are needed to support the competition between APE1 and NEIL2.

We thank the reviewer for pointing this out. We repeated the experiments and added error bars for the previous Figure 2F and 2G (Figure 2E,F in the revised manuscript). We also added western blots for the rescue experiments with NEIL2-HA overexpression (Figure 2E,F in the revised manuscript). However, for the NEIL2 knockdown, we were unable to detect the endogenous NEIL2 using any of the commercially available anti-NEIL2 antibodies that we had tested (abcam, ab180576 showed a non-specific band at \~50 kDa; abcam, ab124106 can only recognize the overexpressed NEIL2).

We also agree with the reviewer that it would be informative if one could design cell-based experiments to support the in vitro competition between APE1 and NEIL2 at AP sites. However, APE1, which aside from its endonuclease activity on AP sites, has numerous additional functions and interactions: including telomere maintenance: Madlener et al., 2013; as a reductive activator of many transcription factors, which is why it's also referred as Ape1/Ref-1 (redox effector factor); and interacts with proteins and factors involved in energy metabolism and homeostasis: Thakur et al., 2014; Tell et al., 2009. Therefore, we could not design an in vivo experiment that would specifically address its endonuclease activity at AP sites versus that of NEIL2. In contrast, the in vitro experiments with purified components are unambiguous in this regard (Figure 4 in the revised manuscript).

> 4\) In Figure 3A, it seems that γH2AX staining increased in all cells upon the expression of A3B and that shNEIL2 diminished this effect but did not completely prevented it as written in the Results section. It would be good to modify the text to reflect this result. In Figure 3D, panel shows the results of a γH2AX assay in the non-mutagenic MDA-MB-453 that were subject to exogeneous expression of both A3B and NEIL2. The control shows a γH2AX assay in A3B expressing cells but the background of γH2AX expression in the parental cells is not shown. Because the experiments aim to measure A3B-mediated γH2AX foci, quantification of such foci in the parental cells is essential for interpreting the results. Additionally, the results from the γH2AX experiments in Figure 3A need to be further supported by immunoblotting for γH2AX and total H2AX. The same concern applies to the experiments in Figure 5B.

We agree with the reviewer and rephrased our original text to "which was markedly decreased in NEIL2-depleted Hs578T cells". For Figure 3D, we added two groups of cells and undertook the immunostaining experiment to show the background of γH2AX foci in the parental cells without A3B overexpression (Figure 3D in the revised manuscript). Regarding Figure 3A and Figure 5B, analysis of γH2AX foci by immunofluorescence is generally considered a sufficient and direct measurement of DNA double-strand breaks (e.g. Morel et al., 2017; Ladstatter et al, Cell. 2016; Kinner et al., Nucleic Acids Res. 2008).

> 5\) APE1 is known to be a poor enzyme for a single-stranded substrate as it needs a double strand to bind and cleave efficiently. Thus, that can explain APE1\'s reduced activity in Figure 4A. For double-stranded substrate APE1 activity seems much faster. Again, the kinetics seems little off as the substrate to product ratio is not consistent. It looks like double-stranded oligo is not a suitable substrate for NEIL2. APE1 is much faster, and a higher concentration of NEIL2 can compete for only 50% activity. Figure 4C and D is very complex to understand; in Figure 4C, it seems NEIL2 is bound to UDG substrate that inhibits APE1 activity. Thus, NEIL2 has slower turnover from the substrate. But Figure 4D demonstrates a higher amount of APE1 facilitates NEIL2 activity. In this regard, measuring dissociation constant from the substrate can be useful to dissect the issue of activity vs. enzyme turnover. Figure 4F aims to test whether processing by NEIL2 creates products that are poor substrates for DNA polymerase β. This is a key point in the paper and quantification is important. In the experiment reported in the current submission, NEIL2 levels vary along with PNKP levels, and interpretation is therefore difficult. It would be useful to perform the NEIL2 dose-response analysis in the presence of a constant level of PNKP.

We thank the reviewer for the comment, and concur that the experiments depicted in Figure 4 as originally described and presented are difficult to understand. Therefore, we added another panel (a new version of Figure 4A) showing a schematic of the expected APE1 and NEIL2 reaction products, and hopefully this is a clearer description of what we did and found. Our original Figure 4A (Figure 4B in the revised manuscript) did not show reduced activity of APE1. Rather, lanes 5 to 7 showed respectively: the lyase products of the combined reaction of NEIL2 and APE1, NEIL2 alone, and APE1 alone on the AP sites generated by UDG. APE1 alone generates a 25-nt-3'OH terminated product (lane 7); NEIL2 generates a 25-nt-3'P terminated product, which migrates somewhat faster than 3'OH-terminated APE1 product (lane 6). When both enzymes were added, only the faster migrating produce was seen (lane 5), indicating it was generated by NEIL2 and that NEIL2 outcompetes APE1 on the single-stranded AP site (Figure 4B in the revised manuscript).

As to the reviewer's comment "It looks like double-stranded oligo is not a suitable substrate for NEIL2. APE1 is much faster, and a higher concentration of NEIL2 can compete for only 50% activity. Figure 4C and D is very complex to understand ....". We think that this comment reflects some misunderstanding on what we did: All of the double-stranded AP-containing substrates (generated by UDG treatment of the U/G mispair) can be digested by either APE1 or NEIL2, as shown in our original Figure 4B (Figure 4C in the revised manuscript). This figure showed concentration curves of the two enzymes, which allowed determination of the amount of either enzyme that was not quite or barely sufficient to digest all of the substrate. We then carried out a competition experiment between NEIL2 and APE1 using increasing amounts of NEIL2 at the two concentrations of APE1: the amount (0.005 U) barely sufficient to digest all of the substrates and a 4-fold higher amount (0.02 U), shown respectively in Figure 4C,D in our original submission.

To make the logic of this experiment clearer, we combined the C and D panels in the original Figure 4 into one panel (Figure 4D in the revised manuscript). Also, we labeled the lanes corresponding to the two concentrations of APE1 as "Low APE1 (0.005U)" and "High APE1 (0.02U)" respectively. Lanes 2 and 3 (Figure 4D in the revised manuscript) are positive controls to show the NEIL2-only (double band) and APE1-only (single band) products. That the distinctive double band NEIL2 product appears at about the same concentration of NEIL2 even at a 4-fold excess of APE1 strongly supports our contention that NEIL2 usurps APE1 at the AP sites. We also rephrased the relevant parts of the text to clarify the description of the Results: subsection "NEIL2 outcompetes APE1 at AP sites" and Legend to Figure 4 in the revised manuscript.

Additionally, as suggested by the reviewer, we performed the incorporation assay in the presence of a constant level of PNKP and increasing amounts of NEIL2, and the result (Figure 4F in the revised manuscript) is consistent with our previous one.

> 6\) A substrate using THF as an AP site substitute can be used as a control. Also using a substrate with 3\'P rather than UDG can be a cleaner set-up to compare.

As AP sites are probably the most common naturally occurring DNA lesions, we felt that they would be the most appropriate substrate for our in vitro studies. Our method using UDG to generate AP sites from U-containing single- or double-stranded oligonucleotides is a well-accepted standard procedure. To confirm the identify of AP sites, we treated the product from the UDG reaction with NaOH, which cleaves the AP sites upon heating at 95°C. The results showed that only the product from the UDG reaction can be cleaved by NaOH treatment (Figure 4---figure supplement 1C in the revised manuscript).

> 7\) Although the authors stated that Exo1 activity is similar for both APE1 and NEIL2 products, Figure 5E shows different substrate to product ratios for two enzymes. Authors might consider adding a panel of APE1 and NEIL2 together in Exo1 activity assay in Figure 5E to understand if the presence of APE1 facilitates or inhibits Exo1 activity.

We thank and concur with the reviewer that we should use equal amounts of APE1 and NEIL2 products to compare the relative activity of Exo1 on these substrates. We therefore repeated this experiment with equivalent levels of NEIL2- and APE1-generated substrates, and showed that both substrates were equally digested by two different concentrations of Exo1 (Figure 5E in the revised manuscript).

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The authors have addressed an important concern, providing better descriptions of the specialized methodology used in the paper. The authors have also removed some controversial data from the paper, resulting in a succinct, readable and focused report. However, some controls are still missing:
>
> 1\) An experimental validation of the proposed competition between APE1 and NEIL2 (usurpation of APEI by NEIL2) is critical. A ChIP-seq or a chromatin binding assay can be used for this purpose. If validated, this point is potentially very important, as is emphasized in the Abstract.

The following two points summarize the current state of how we had experimentally validated the proposed competition between APE1 and NEIL2 for abasic (AP) sites, which we had termed usurpation of APE1 by NEIL2. In our revised manuscript we repeated some of these experiments and made all the modifications suggested in the review of our original submission:

1\) Our current Figures 4 and 5 unambiguously show with purified proteins that, depending on their relative concentrations, NEIL2 outcompetes (usurps) APE1 on a defined AP site, interferes with the subsequent Polβ step of base excision repair (BER) and generates a substrate susceptible to Exo1, which would generate a single-stranded A3B deaminase substrate.

2\) We recapitulated the essential elements of this finding in vivo by showing that overexpressing NEIL2 in the MDA-MB-453 cell line, which has low expression of NEIL2, induces both U/G repair-mediated A3B mutations (Figure 2F) and DNA double strand breaks (Figure 3D) as measured by immunofluorescence of γH2AX foci. We stress here that while NEIL2 is biochemically unable to process a U/G site (Figure 4---figure supplement 1B), it can process and cleave the AP site generated from U/G by a U/G-specific glycosylase (Figure 4C).

The reviewer suggests that "A ChIP-seq or a chromatin binding assay can be used for this purpose". ChIP-seq is normally used to determine sequences targeted by nucleic-binding proteins after their immunoprecipitation by a cognate antibody. In our case, the targeted sequence would be an AP site. Is the idea here to compare the relative numbers of AP sites targeted by NEIL2 and APE1 in the cancer cell lines that differ in repair-mediated mutation? Aside from the fact that there is no good NEIL2 antibody available, the AP site is a substrate for both enzymes and would presumably be eliminated by their enzymatic activity upon binding. It is infeasible for us to score such an outcome. Chromatin binding assay has been used to directly detect binding of proteins to chromatin. Is it suggested that we compare the binding of APE1 and NEIL2 to bulk chromatin? Even if we could control for the likely non-specific binding of these proteins to bulk chromatin, we do not think this experiment could supplement the unambiguous competition for AP sites that we identified using purified components (Figure 4A-D).

> 2\) Due to the absence of appropriate measurements of protein levels (for example, NEIL2 and APE1 in nuclear extracts that show variable activity in deaminase assays) it is not possible to rule out that the observations reported in the paper might be explained by alternative mechanisms. If appropriate antibodies are not available, these other mechanisms should at least be discussed.

Given that the results presented in Figures 4 and 5 are congruent with the known elements of BER and its perturbation by NEIL2, we have proposed what seems to be the most straightforward mechanism for these results. However, the reviewer makes a good point and we have modified the relevant part of our Discussion accordingly. The relevant text now reads:

"Therefore, the most parsimonious explanation of our results is that NEIL2 diverts BER to Exo1-generation of single-stranded DNA that would be vulnerable to A3B deaminase (Figure 5F). \[...\] The inherent reductive power of a biochemical experiment using purified components is its ability to reveal the prevailing baseline conditions of a process (Figure 5F)."

In addition, we would be pleased to consider and discuss other mechanisms that the reviewer suggests.

> 3\) The authors are correct to suggest that immunofluorescence is an acceptable measure of DNA damage in some literature. However, because of the high signal-to-noise ratio in the current submission, the paper would still benefit from another measurement of the extent of DNA damage based on a different method, for example, immunoblotting of γH2AX vs. total H2AX.

The reviewer implied that because of the "high signal-to-noise ratio" we should consider an additional assay for γH2AX. But a "high signal-to-noise ratio" is usually considered a good feature of an assay, which is what our immunofluorescence results showed and agreed with previous assays for γH2AX foci in Hs578T cells (Morel et al., 2017). The reviewer correctly states that immunoblotting of γH2AX vs. H2AX has been used to measure the double strand breaks (Burma et al., J. Biol. Chem. 2001). However, as we wrote in our previous response to reviewers' comment \#4 in the first round of revision, quantification of γH2AX foci by immunofluorescence is the most widely used, direct and accurate way to quantify double strand breaks in cells (Morel et al., 2017; Ladstatter et al., Cell, 2016; Lobrich et al., Cell Cycle, 2010; Kinner et al., Nucleic AcidsRes. 2008), which is why we chose this method.

> For the quantification of immunofluorescent signals in Figure 3 (A, right panel, C and D): what does the y-axis (% of γH2AX positive cells) refer to? Does each data point refer to a replicate experiment, or was the percentage of positive cells determined in each field in a single imaging experiment? How significant are the changes induced by the two shNEIL2 when compared to control levels?

We thank the editor and the reviewer for pointing this out. In Figure 3A, C, and D, the y-axis refers to "the percentage of cells with γH2AX foci". Each data point is derived from a randomly selected microscopic field in two replicate experiments (Line 852-853, 863, and 868 of the figure legends of this version of the revised manuscript). The control for the two shNEIL2 (column 3 and 4 in both panels of Figure 3A) is the data shown in column 2 because NEIL2 is the only variable in this experiment (A3B-3HA was overexpressed for these three columns but not for column 1). We have added the relevant statistical analysis to the figure (Figure 3A in the revised manuscript).
